US28176E1082 - Common Stock - After market: 87.26 +0.08 (+0.09%)
NYSE:EW (10/4/2022, 7:23:54 PM)+1.72 (+2.01%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Equipment & Supplies|
|Earnings (Last)||07-28 2022-07-28/amc||Earnings (Next)||10-26 2022-10-26/amc|
|Ins Owners||0.16%||Inst Owners||175.66%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,700 full-time employees. The company went IPO on 2000-03-27. The firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. The company also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA 92614
CEO: Michael A. Mussallem
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years. Minimally invasive surgical procedures have entered the limelight within the global healthcare space. Incidences of surgical wounds and corresponding […]
/PRNewswire/ -- The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years....
/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two...
/PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough...
Here you can normally see the latest stock twits on EW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.